1-4 of 4
Tim Wassenaar
Close
Sort by
Journal Articles

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre, Christopher D Fletcher, Saurabh A Rajguru, Priyanka A Pophali, Mariah Endres, Mitch Howard, Tim Wassenaar, Ruth Callaway Warren, Ryan J Mattison, Kari B Wisinski, Julie E Chang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4407.
https://doi.org/10.1182/blood-2023-173871
Published: 2023
Journal Articles

Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F List, MD, Zhuoxin Sun, PhD, Amit Verma, MD, John M. Bennett, MD, Kathy L McGraw, PhD, Lisa Ann Nardelli, BS, Jaroslaw P Maciejewski, MD PhD FACP, Jessica K Altman, MD, Puneet Cheema, MD, David F. Claxton, MD, Rami S. Komrokji, MD, Selina Luger, MD, Ryan Mattison, MD, Tim Wassenaar, MD, Andrew Artz, MD, Charles A Schiffer, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2016) 128 (22): 223.
https://doi.org/10.1182/blood.V128.22.223.223
Published: 2016
Journal Articles

Weekly Temsirolimus and Bortezomib For Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Phase II Study

Timothy S. Fenske, MD, KyungMann Kim, PhD, Chong Zhang, MS, John P. Farnen, MD, FACP, Adedayo A. Onitilo, MD, Jules H. Blank, MD, Harish Ahuja, MD, Tim Wassenaar, MD, Rubina Qamar, MD, Patrick Mansky, MD, Anne Traynor, MD, Ryan J. Mattison, MD, Brad S. Kahl, MD
Journal: Blood
Blood (2013) 122 (21): 3035.
https://doi.org/10.1182/blood.V122.21.3035.3035
Published: 2013
Journal Articles

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study

Julie E. Chang, MD, Chong Zhang, KyungMann Kim, PhD, Rachel Kirby, Lynn Volk, Jae Werndli, Ronald S. Go, MD, Matthias Weiss, MD, PhD, Jules H. Blank, MD, Michael A. Thompson, MD, PhD, John P. Farnen, MD, FACP, Craig E. Cole, MD, Ali W. Bseiso, MBBS, Michael Volk, MD, Gerald Bayer, MD, Tim Wassenaar, MD, Patrick Mansky, MD, Anne Traynor, Timothy S. Fenske, MD, Brad S. Kahl, M.D.
Journal: Blood
Blood (2012) 120 (21): 3647.
https://doi.org/10.1182/blood.V120.21.3647.3647
Published: 2012